Then, during pressure overload-induced cardiac hypertrophy, MA treatment decreased the hypertrophic markers, improved the cardiac function, and restricted cardiac fibrosis by inhibiting the activation of protein kinase B (AKT) and extracellular regulated protein kinases (ERK) signaling pathway (21). The gene discussed is AKT1; the disease is cardiac hypertrophy.